AGEN
Agenus Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.26
+0.18%Year over year
Reported trailing growth
- Revenue
- +30.5%
- EBITDA
- +307.9%
- EBIT
- +141.4%
- EPS
- +138.0%
- Free cash flow
- +23.0%
- Operating cash flow
- +22.9%
Forward estimates
Based on analyst estimates
- Revenue
- -2.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.2%
- EBITDA
- +161.4%
- EBIT
- +82.9%
- Net income
- +100.1%
- EPS
- +100.0%
- Free cash flow
- +0.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026